These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 32671117)

  • 61. Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.
    Sanlorenzo M; Vujic I; Moy A; Quaglino P; Fierro MT; Gammaitoni L; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Expert Opin Biol Ther; 2015; 15(10):1491-500. PubMed ID: 26206099
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
    Zou P; Tang R; Luo M
    Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Immunotherapy of melanoma].
    Dréno B
    Bull Acad Natl Med; 2010 Oct; 194(7):1373-81. PubMed ID: 22043632
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of immunotherapy and surgery for stage IV melanoma.
    Molina G; Kasumova GG; Qadan M; Boland GM
    Cancer; 2020 Jun; 126(11):2614-2624. PubMed ID: 32157676
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Contribution of B lymphocytes in acquired resistance to targeted therapies in metastatic melanoma].
    Fourneaux C; Dubois B
    Med Sci (Paris); 2018 Oct; 34(10):875-878. PubMed ID: 30451659
    [No Abstract]   [Full Text] [Related]  

  • 66. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
    Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
    Front Immunol; 2021; 12():788499. PubMed ID: 34956219
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
    Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
    Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
    Damian DL; Saw RP; Thompson JF
    J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
    Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Melanoma update].
    Longvert C; Saiag P
    Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [What's new in skin cancers?].
    Jouary T
    Ann Dermatol Venereol; 2014 Dec; 141 Suppl 4():S630-42. PubMed ID: 25539755
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adjuvant immunotherapy for melanoma patients: progress and opportunities.
    Sussman TA; Ott PA
    ESMO Open; 2024 May; 9(5):102962. PubMed ID: 38626633
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
    Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
    Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers.
    He R; Lu J; Feng J; Lu Z; Shen K; Xu K; Luo H; Yang G; Chi H; Huang S
    Front Immunol; 2024; 15():1435187. PubMed ID: 39026661
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
    Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
    BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.